CriticalSynthetic opioid, full mu-receptor agonist×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
Selegiline irreversibly inhibits monoamine oxidase (MAO), selectively type B at recommended doses, and above 10 mg a day it may lose its selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Methadone is a synthetic opioid and a pure opioid receptor agonist (methadone SmPC, AEMPS, section 5.1). According to the Spanish methadone SmPC, MAO inhibitors can enhance and prolong its depressant effects or, conversely, stimulate the central nervous system, and serotonin syndrome can occur with this combination (methadone SmPC, AEMPS, section 4.5). According to the US methadone label, interactions of MAO inhibitors with opioids may present as serotonin syndrome or opioid toxicity (methadone label, US Food and Drug Administration, FDA, section 7). The US label for selegiline tablets states that the serious, sometimes fatal reactions between opioids, including methadone, and MAO inhibitors also concern selective MAO-B inhibitors (FDA selegiline label, section 7.1). The two drugs do not interact through liver enzymes: selegiline does not inhibit the cytochrome P450 (CYP) enzymes that metabolise methadone (FDA selegiline and methadone labels, section 12.3).
Symptoms
Serotonin syndrome with methadone and monoamine oxidase (MAO) inhibitors or other serotonergic drugs presents with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination, rigidity), nausea, vomiting and diarrhoea (methadone label, US Food and Drug Administration, FDA, section 5.9). It usually starts within several hours to a few days of combined use, but may start later (FDA methadone label, section 5.9). The other form of this interaction is opioid toxicity with respiratory depression and coma (FDA methadone label, section 7). According to the Spanish methadone summary of product characteristics (SmPC), MAO inhibitors can enhance and prolong the depressant effects of methadone or stimulate the central nervous system (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Opioids, including methadone, combined with MAO inhibitors have caused serious, sometimes fatal reactions (FDA selegiline label, section 7.1).
Management
The combination is contraindicated. The Spanish selegiline summary of product characteristics (SmPC) prohibits selegiline with opioids as a group, with pethidine given only as an example (selegiline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3). According to its own SmPC, methadone is an opioid (methadone SmPC, AEMPS, section 5.1). The Spanish methadone SmPCs contraindicate methadone with monoamine oxidase (MAO) inhibitors and within 2 weeks of stopping them (methadone SmPC, AEMPS, sections 4.3 and 4.5). According to its own SmPC, selegiline is an MAO type B inhibitor (selegiline SmPC, AEMPS, section 5.1). The US label for selegiline tablets contraindicates methadone by name (selegiline label, US Food and Drug Administration, FDA, sections 4 and 7.1). The US methadone label is milder: it does not recommend methadone in patients taking MAO inhibitors or within 14 days of stopping them (FDA methadone label, section 7). Start methadone no earlier than 2 weeks after stopping selegiline (methadone SmPC, AEMPS, sections 4.3 and 4.5; FDA selegiline label, sections 4 and 7.1), and do not start an MAO inhibitor while the patient is taking methadone (FDA methadone label, section 17). The documents give no interval between the last dose of methadone and the first selegiline tablet. For transdermal selegiline, which is not authorised in Spain (AEMPS medicines register), the US label says to wait 4–5 half-lives of the drug or its active metabolite, about one week (transdermal selegiline FDA label, section 4). If serotonin syndrome is suspected, stop methadone (FDA methadone label, section 5.9). Warn patients taking selegiline that pethidine and some other painkillers must not be used with it (FDA selegiline label, section 17).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- FDA: Emsam (selegiline transdermal system) prescribing information (2020)– FDA label, Viatris Specialty LLC, DailyMed setid b891bd9f-fdb8-4862-89c5-ecdd700398a3, revised 05/2020, section 4
- FDA: Methadone hydrochloride tablets (methadone) prescribing information (2025)– FDA, DailyMed setid 4a44bde6-c348-4316-b0e0-c24b407cb823 (VistaPharm), versión 17, revisión 12/2025, secciones 5.4, 5.9 y 7
- AEMPS: Ficha técnica: Metadona, Metasedin 40 mg comprimidos (nº registro 62423), sección 4.3 (2026)– AEMPS, CIMA, nº registro 62423 (Metasedin 40 mg comprimidos, Esteve Pharmaceuticals), revisión 05/2026, secciones 4.3, 4.5 y 5.1